UK Sees Surge in Shingles Vaccine Demand Amid Dementia Protection Hopes

Demand for the shingles vaccine has more than doubled in the UK's Boots pharmacy chain over the past year, with many individuals opting to pay out-of-pocket for the inoculation. This surge is partly driven by recent studies suggesting the vaccine may offer protection against dementia, in addition to its primary purpose of preventing the painful shingles rash and its complications. Boots reported a 30% increase in orders in the year ending September 2025 and a more than twofold increase in the following year, with a full two-dose course costing £460 privately. The Superdrug chain also saw a 41% rise in orders.

The UK's National Health Service (NHS) provides the vaccine free only to certain individuals aged 65 and over and to the immunocompromised. The increased demand includes many people under 65 who are not eligible for the free vaccine and are paying for it themselves. The shingles vaccine, particularly the newer Shingrix formulation, is highly effective at preventing shingles and its associated long-term nerve pain, known as postherpetic neuralgia. It is recommended for all individuals aged 50 and above, as well as those 18 and older with compromised immune systems or other increased risk factors.

Research, including a significant study published in Nature in April 2025, analyzed medical records of over 280,000 adults in Wales. This study suggested that an older shingles vaccine, Zostavax, reduced the likelihood of a new dementia diagnosis by approximately 20% over a seven-year follow-up period, with a stronger effect observed in women. This finding was based on a "natural experiment" comparing individuals born just before and after a specific eligibility date for the vaccine program. Further analysis from the same team, published in Cell in December 2025, linked the vaccine to a reduction in mild cognitive impairment diagnoses and fewer deaths among those already living with dementia.

However, the link between shingles vaccination and dementia prevention is still under investigation, and definitive proof is lacking. A pre-print study from England in July 2026, analyzing over 6.3 million hospital records, found no evidence of a reduction in dementia diagnoses among those eligible for the older vaccine, despite a clear decrease in shingles diagnoses. Researchers emphasize that observational studies cannot prove causation and that more controlled trials are needed. Potential mechanisms being explored include the idea that the virus reactivation and associated inflammation might contribute to neurological damage, and the vaccine's ability to reduce this reactivation could offer indirect protection.

In Israel, the trend appears to be the opposite, with a notable decrease in vaccinations across major health funds like Clalit, Maccabi, and Leumit in the past year. For instance, Clalit saw a nearly 30% drop in vaccinations compared to the previous year. While the newer Shingrix vaccine is included in Israel's health basket for those 65 and older and the immunocompromised, it is also available at a discount through supplementary insurance for those aged 50 and above. The primary reason for vaccination in Israel remains the prevention of shingles and its complications, with the potential dementia benefit still considered an area for further research.